Aurinia Presents Safety and Efficacy Profile of LUPKYNIS for People with Lupus Nephritis at European Alliance of Associations for Rheumatology Congress 2024
AUPH Stock | USD 9.20 0.22 2.45% |
Under 70 percent of all Aurinia Pharmaceuticals' traders are curious in acquiring. The analysis of the overall investor sentiment regarding Aurinia Pharmaceuticals suggests that a large number of traders are confidant. Aurinia Pharmaceuticals' investing sentiment shows overall attitude of investors towards Aurinia Pharmaceuticals.
Aurinia |
Aurinia Pharmaceuticals Inc. , today announced an oral presentation at the European Alliance of Associations fo
Read at businesswire.com
Aurinia Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Aurinia Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Aurinia Pharmaceuticals Fundamental Analysis
We analyze Aurinia Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aurinia Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aurinia Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Aurinia Pharmaceuticals is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Aurinia Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aurinia Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aurinia Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aurinia Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Aurinia Pharmaceuticals Related Equities
BTAI | BioXcel Therapeutics | 6.43 | ||||
TGTX | TG Therapeutics | 1.15 | ||||
MDGL | Madrigal Pharmaceuticals | 0.30 | ||||
EXEL | Exelixis | 0.65 | ||||
PTCT | PTC Therapeutics | 1.33 | ||||
AXSM | Axsome Therapeutics | 1.44 | ||||
SRPT | Sarepta Therapeutics | 1.52 | ||||
TERN | Terns Pharmaceuticals | 1.87 | ||||
AKRO | Akero Therapeutics | 2.22 | ||||
VKTX | Viking Therapeutics | 3.56 | ||||
MCRB | Seres Therapeutics | 3.61 | ||||
HEPA | Hepion Pharmaceuticals | 4.00 |
Complementary Tools for Aurinia Stock analysis
When running Aurinia Pharmaceuticals' price analysis, check to measure Aurinia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurinia Pharmaceuticals is operating at the current time. Most of Aurinia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aurinia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurinia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aurinia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Transaction History View history of all your transactions and understand their impact on performance | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |